Test Code GQ1ES Ganglioside GQ1b Antibody, IgG, ELISA, Serum
Necessary Information
Provide the following information:
1. Relevant clinical information
2. Ordering provider name, phone number, mailing address, and email address
Specimen Required
Patient Preparation: For optimal antibody detection, specimen collection is recommended to occur prior to initiation of immunosuppressant medication or intravenous immunoglobulin treatment.
Supplies: Sarstedt Aliquot Tube, 5 mL (T914)
Collection Container/Tube:
Preferred: Red top
Acceptable: Serum gel
Submission Container/Tube: Plastic vial
Specimen Volume: 1 mL
Collection Instructions: Centrifuge and aliquot serum into a plastic vial.
Secondary ID
621107Useful For
Evaluating patients with an underlying demyelinating neuropathy
Supporting the diagnosis of a ganglioside GQ1b IgG-related disorder
Method Name
Enzyme-Linked Immunosorbent Assay (ELISA)
Reporting Name
GQ1b-IgG ELISA, SSpecimen Type
SerumSpecimen Minimum Volume
0.5 mL
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Serum | Refrigerated (preferred) | 28 days | |
Frozen | 28 days | ||
Ambient | 72 hours |
Reject Due To
Gross hemolysis | Reject |
Gross lipemia | Reject |
Gross icterus | Reject |
Clinical Information
Ganglioside GQ1b antibody (GQ1b IgG) is a biomarker for a group of related disorders that includes Miller Fisher syndrome (MFS), Bickerstaff brainstem encephalitis (BBE), and classic Guillain–Barre syndrome (GBS) with ophthalmoplegia. Collectively, these are referred to GQ1b IgG-related syndromes. The prevalence of GQ1b IgG in this population of patients is high and has been reported to be greater than 80% in well-defined clinical cohorts. In classic GBS, the prevalence of GQ1b IgG positivity is low but has been reported in the literature. Patients with GQ1b IgG-related disorders may not require immunotherapy, presumably because they have a good prognosis and spontaneous recovery. In severe cases, both intravenous immunoglobulin (IVIG) and plasma exchange are effective treatments for MFS and BBE. In patients with a clinical suspicion of MFS and related disorders, positivity for GQ1b IgG supports the specific clinical diagnosis and may also provide prognostic information. Although the diagnosis of these disorders is dependent on clinical evaluation and electrophysiologic studies, assessment of GQ1b IgG can further support the diagnosis.
Reference Values
Negative
Interpretation
A positive result is consistent with an immune-mediated demyelinating neuropathy and correlation with clinical electrodiagnostic features is recommended.
Ganglioside GQ1b (GQ1b) IgG antibodies occur in Miller Fisher syndrome, Bickerstaff brainstem encephalitis, and atypical Guillain-Barre syndromes having variably present demyelinating neuropathy, ophthalmoplegia, ataxia, brainstem features with encephalitis and, less commonly, other neurogenic conditions.
A negative result does not exclude an immune-mediated demyelinating neuropathy nor a GQ1b IgG syndrome.
CPT Code Information
83516
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
GQ1ES | GQ1b-IgG ELISA, S | 63254-7 |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
621107 | GQ1b-IgG ELISA, S | 63254-7 |
Forms
If not ordering electronically, complete, print, and send a Neurology Specialty Testing Client Test Request (T732) with the specimen.